ReviewVeterinary world2019
Current therapeutic applications and pharmacokinetic modulations of ivermectin.
Review in Veterinary world, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- Evolution of Ivermectin Resistance in the Nematode ModelEvolutionary applications · 2026Article
- Eradication of Aspiculuris tetraptera in various immunodeficient mouse models using ivermectin: a case report.Laboratory animal research · 2026Article
- Global research hotspots, trends, and future directions of ivermectin research: an informatics investigation (2020-2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Therapeutic and Formulation Advances of Ivermectin in Veterinary and Human Medicine.Pharmaceutics · 2025Review
- Co-Processed Crystalline Solids of Ivermectin with SpanAAPS PharmSciTech · 2024Article
- Formulation and optimization of ivermectin nanocrystals for enhanced topical delivery.International journal of pharmaceutics: X · 2023Article
- Electrochemical Characterisation and Confirmation of Antioxidative Properties of Ivermectin in Biological Medium.Molecules (Basel, Switzerland) · 2023Article
- Ivermectin Attenuates CClInternational journal of molecular sciences · 2022Article
- The epidemiology and control ofParasite epidemiology and control · 2022Article
- Marine Actinomycetes, New Sources of Biotechnological Products.Marine drugs · 2021Review
- Ivermectin as a potential treatment for COVID-19?PLoS neglected tropical diseases · 2021Article
- Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.Archives of toxicology · 2021Review
- Article
- Innovative anthelmintic based on mechanochemical technology and their efficacy against parasitic infection of sheeps.Journal of advanced veterinary and animal research · 2020Article
- Coronavirus Disease 2019-COVID-19.Clinical microbiology reviews · 2020Review
- Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.Annals of clinical microbiology and antimicrobials · 2020Article
- A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.Frontiers in pharmacology · 2020Review
- The use of Ivermectin for the treatment of COVID-19: Panacea or enigma?Clinical epidemiology and global healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ivermectin is considered to be a wonder drug due to its broad-spectrum antiparasitic activity against both ectoparasites and endoparasites (under class of endectocide) and has multiple applications in both veterinary and human medicine. In particular, ivermectin is commonly used in the treatment of different kinds of infections and infestations. By altering the vehicles used in the formulations, the pharmacokinetic properties of different ivermectin preparations can be altered. Since its development, various vehicles have been evaluated to assess the efficacy, safety, and therapeutic systemic concentrations of ivermectin in different species. A subcutaneous route of administration is preferred over a topical or an oral route for ivermectin due to superior bioavailability. Different formulations of ivermectin have been developed over the years, such as stabilized aqueous formulations, osmotic pumps, controlled release capsules, silicone carriers, zein microspheres, biodegradable microparticulate drug delivery systems, lipid nanocapsules, solid lipid nanoparticles, sustained-release ivermectin varnish, sustained-release ivermectin-loaded solid dispersion suspension, and biodegradable subcutaneous implants. However, several reports of ivermectin resistance have been identified in different parts of the world over the past few years. Continuous use of suboptimal formulations or sub-therapeutic plasma concentrations may predispose an individual to resistance toward ivermectin. The current research trend is focused toward the need for developing ivermectin formulations that are stable, effective, and safe and that reduce the number of doses required for complete clinical cure in different parasitic diseases. Therefore, single-dose long-acting preparations of ivermectin that provide effective therapeutic drug concentrations need to be developed and commercialized, which may revolutionize drug therapy and prophylaxis against various parasitic diseases in the near future. The present review highlights the current advances in pharmacokinetic modulation of ivermectin formulations and their potent therapeutic applications, issues related to emergence of ivermectin resistance, and future trends of ivermectin usage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.